Tramadol controlled release - e-Therapeutics

Drug Profile

Tramadol controlled release - e-Therapeutics

Alternative Names: ETS-6103; ETX6103; Tramadol extended release - e-Therapeutics; Tramadol hydrochloride; Tramadol sustained release - e-Therapeutics; Viotra

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator e-Therapeutics
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Erectile dysfunction therapies; Opioid analgesics; Phenyl ethers; Small molecules
  • Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 22 Mar 2016 e-Therapeutics completes a phase IIb trial for Major depressive disorder in the United Kingdom (NCT02014363) prior to March 2016
  • 08 Mar 2016 Biomarkers information updated
  • 07 Jan 2016 Tramadol controlled release - e-Therapeutics is available for licensing as of 07 Jan 2016. http://www.etherapeutics.co.uk/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top